NASDAQ:OVID - Ovid Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.59 +0.08 (+1.77 %)
(As of 11/18/2018 04:00 PM ET)
Previous Close$4.59
Today's Range$4.19 - $4.67
52-Week Range$4.16 - $12.44
Volume23,911 shs
Average Volume44,779 shs
Market Capitalization$113.16 million
P/E Ratio-1.37
Dividend YieldN/A
Beta1.15
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate that is in Phase Ib/IIa trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the clinical setting. The company has collaboration agreement with Takeda Pharmaceutical Company Limited. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.

Receive OVID News and Ratings via Email

Sign-up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OVID
Previous Symbol
CUSIPN/A
Phone646-661-7661

Debt

Debt-to-Equity RatioN/A
Current Ratio5.30
Quick Ratio5.30

Price-To-Earnings

Trailing P/E Ratio-1.37
Forward P/E Ratio-2.19
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.03 per share
Price / Book2.26

Profitability

EPS (Most Recent Fiscal Year)($3.35)
Net Income$-64,800,000.00
Net MarginsN/A
Return on Equity-75.08%
Return on Assets-67.37%

Miscellaneous

Employees43
Outstanding Shares24,650,000
Market Cap$113.16 million
OptionableNot Optionable

Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions

What is Ovid Therapeutics' stock symbol?

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics Inc (NASDAQ:OVID) released its quarterly earnings data on Thursday, November, 8th. The company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.60) by $0.07. View Ovid Therapeutics' Earnings History.

When is Ovid Therapeutics' next earnings date?

Ovid Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, April 4th 2019. View Earnings Estimates for Ovid Therapeutics.

What price target have analysts set for OVID?

4 brokers have issued twelve-month price targets for Ovid Therapeutics' stock. Their predictions range from $20.00 to $27.00. On average, they expect Ovid Therapeutics' stock price to reach $23.50 in the next twelve months. This suggests a possible upside of 412.0% from the stock's current price. View Analyst Price Targets for Ovid Therapeutics.

What is the consensus analysts' recommendation for Ovid Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ovid Therapeutics.

Has Ovid Therapeutics been receiving favorable news coverage?

Headlines about OVID stock have trended neutral on Sunday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ovid Therapeutics earned a news impact score of 0.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future.

Who are some of Ovid Therapeutics' key competitors?

Who are Ovid Therapeutics' key executives?

Ovid Therapeutics' management team includes the folowing people:
  • Dr. Jeremy Max Levin, Chairman & CEO (Age 65)
  • Dr. Matthew J. During, Founder, Pres, Chief Scientific Officer, Director & Member of Scientific Advisory Board (Age 61)
  • Ms. Lora Pike, Sr. Director of Investor Relations & PR
  • Ms. Ana C. Ward Esq., M.S., M.B.A., Sr. VP, Gen. Counsel & Secretray (Age 50)
  • Ms. Suzanne K. Wakamoto SPHR, SHRM-SCP, Sr. VP of HR

When did Ovid Therapeutics IPO?

(OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Who are Ovid Therapeutics' major shareholders?

Ovid Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (4.12%), Redmile Group LLC (2.96%), Baker BROS. Advisors LP (0.90%), Granite Point Capital Management L.P. (0.45%), Dimensional Fund Advisors LP (0.32%) and JPMorgan Chase & Co. (0.22%). Company insiders that own Ovid Therapeutics stock include Douglas E Williams and Jeremy M Levin. View Institutional Ownership Trends for Ovid Therapeutics.

Which major investors are selling Ovid Therapeutics stock?

OVID stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Granite Point Capital Management L.P. and Baker BROS. Advisors LP. View Insider Buying and Selling for Ovid Therapeutics.

Which major investors are buying Ovid Therapeutics stock?

OVID stock was bought by a variety of institutional investors in the last quarter, including Redmile Group LLC, Dimensional Fund Advisors LP, JPMorgan Chase & Co. and JPMorgan Chase & Co.. Company insiders that have bought Ovid Therapeutics stock in the last two years include Douglas E Williams and Jeremy M Levin. View Insider Buying and Selling for Ovid Therapeutics.

How do I buy shares of Ovid Therapeutics?

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ovid Therapeutics' stock price today?

One share of OVID stock can currently be purchased for approximately $4.59.

How big of a company is Ovid Therapeutics?

Ovid Therapeutics has a market capitalization of $113.16 million. The company earns $-64,800,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. Ovid Therapeutics employs 43 workers across the globe.

What is Ovid Therapeutics' official website?

The official website for Ovid Therapeutics is http://www.ovidrx.com.

How can I contact Ovid Therapeutics?

Ovid Therapeutics' mailing address is 1460 BROADWAY SUITE 15044, NEW YORK NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]


MarketBeat Community Rating for Ovid Therapeutics (NASDAQ OVID)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  191 (Vote Outperform)
Underperform Votes:  153 (Vote Underperform)
Total Votes:  344
MarketBeat's community ratings are surveys of what our community members think about Ovid Therapeutics and other stocks. Vote "Outperform" if you believe OVID will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OVID will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel